Plain-English translation of NCT03977233 on ClinicalTrials.gov ↗ ·
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a chemotherapy combination called FOLFIRINOX in people with pancreatic cancer that hasn't spread to other parts of the body. The study wants to understand whether the specific genetic and cellular characteristics of each patient's tumor can predict how well the medication will work—and whether surgery might become possible after treatment.
Pancreatic cancer is very difficult to treat, and doctors don't yet know which patients will respond best to chemotherapy. By studying the molecular features of tumors before and after treatment with this medication, researchers hope to personalize care and improve outcomes for future patients.
You likely qualify if…
You likely don't qualify if…
You will receive chemotherapy infusions as an outpatient every 2 weeks for a planned 12 cycles (about 6 months). Before treatment begins and after 8 cycles, you'll have a needle biopsy to collect a small sample of your tumor for genetic testing. You'll also have imaging scans every 8 weeks to see how the tumor is responding. If scans show your cancer has shrunk enough to be surgically removable, your doctor may recommend surgery after 8 cycles, with the remaining 4 cycles given afterward. You'll be followed for 3 years after finishing treatment to monitor your health.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States